Revolution Medicines Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Hello. My name is Michael Schmidt. I'm a biotech research analyst with Guggenheim Securities. And it's my great pleasure to welcome Mark Goldsmith, CEO of Revolution Medicines. Welcome, Mark, and thanks for joining us.
Thanks, Michael, really appreciate the opportunity.
Questions & Answers
Revolution Medicines is perhaps the most advanced company pursuing development of so-called RAS(ON) inhibitors or RAS GTP inhibitors, which is different from what others are doing at the moment. And so can you just help us understand why that is important and what the underlying mechanism of your pipeline in that regard is?
Sure. When we refer to RAS-dependent cancers, which of course, is the focus of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
